Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-LIVR phase 3 trial of lonafarnib/ritonavir with or without peginterferon alfa-2a in chronic hepatitis D
MOH_2019-05-30_006022Phase 3Recruiting
- Sponsor
- Eiger BioPharmaceuticals, Inc.
- Start
- May 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lonafarnib, ritonavir and peginterferon alfa-2a in Chronic Viral Hepatitis B With Delta-Agent (4 arms), sponsored by Eiger BioPharmaceuticals, Inc. Primary endpoints: Composite virologic and biochemical response at end of treatment for lonafarnib/ritonavir versus placebo and Composite virologic and biochemical response at end of treatment for lonafarnib/ritonavir plus peginterferon alfa-2a versus placebo. Started May 2019; status: recruiting.
02
Drugs
lonafarnibritonavirpeginterferon alfa-2a
03
Conditions
Chronic Viral Hepatitis B With Delta-Agent
Beyond the preview
Go deeper on MOH_2019-05-30_006022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-30_006022.